JP2023025202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023025202A5 JP2023025202A5 JP2022194533A JP2022194533A JP2023025202A5 JP 2023025202 A5 JP2023025202 A5 JP 2023025202A5 JP 2022194533 A JP2022194533 A JP 2022194533A JP 2022194533 A JP2022194533 A JP 2022194533A JP 2023025202 A5 JP2023025202 A5 JP 2023025202A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antibody fragment
- domain
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 19
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 11
- 210000003719 b-lymphocyte Anatomy 0.000 claims 7
- 239000000611 antibody drug conjugate Substances 0.000 claims 6
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 230000001717 pathogenic effect Effects 0.000 claims 5
- 210000004180 plasmocyte Anatomy 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 210000001806 memory b lymphocyte Anatomy 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000002482 oligosaccharides Polymers 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166729 | 2014-04-30 | ||
| EP14166729.5 | 2014-04-30 | ||
| JP2020142486A JP7189913B2 (ja) | 2014-04-30 | 2020-08-26 | Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020142486A Division JP7189913B2 (ja) | 2014-04-30 | 2020-08-26 | Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023025202A JP2023025202A (ja) | 2023-02-21 |
| JP2023025202A5 true JP2023025202A5 (https=) | 2023-04-14 |
Family
ID=50677985
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565168A Active JP6755805B2 (ja) | 2014-04-30 | 2015-04-30 | Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体 |
| JP2020142486A Active JP7189913B2 (ja) | 2014-04-30 | 2020-08-26 | Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体 |
| JP2022194533A Pending JP2023025202A (ja) | 2014-04-30 | 2022-12-05 | Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565168A Active JP6755805B2 (ja) | 2014-04-30 | 2015-04-30 | Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体 |
| JP2020142486A Active JP7189913B2 (ja) | 2014-04-30 | 2020-08-26 | Ｃｄ２６９（ｂｃｍａ）に対するヒト化抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10144782B2 (https=) |
| EP (1) | EP3137500A1 (https=) |
| JP (3) | JP6755805B2 (https=) |
| KR (3) | KR102632731B1 (https=) |
| CN (2) | CN106661109B (https=) |
| AU (1) | AU2015254526B2 (https=) |
| BR (1) | BR112016024546A2 (https=) |
| IL (2) | IL303667A (https=) |
| MX (2) | MX375800B (https=) |
| NZ (1) | NZ725701A (https=) |
| RU (2) | RU2749041C2 (https=) |
| SG (1) | SG11201608415QA (https=) |
| UA (1) | UA121031C2 (https=) |
| WO (1) | WO2015166073A1 (https=) |
| ZA (1) | ZA201607018B (https=) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6694712B2 (ja) | 2012-11-01 | 2020-05-20 | マックス−デルブルック−セントラム フアー モレキュラーレ メデジン | Ｃｄ２６９（ｂｃｍａ）に対する抗体 |
| CA2900529A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
| KR102632731B1 (ko) * | 2014-04-30 | 2024-02-01 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Ｃｄ269에 대한 인간화 항체 |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| EP3283520B1 (en) | 2015-04-13 | 2020-05-06 | Pfizer Inc | Chimeric antigen receptors targeting b-cell maturation antigen |
| PL3988117T3 (pl) | 2015-04-13 | 2025-03-10 | Pfizer Inc. | Przeciwciała terapeutyczne i ich zastosowania |
| ES2898329T3 (es) | 2016-01-12 | 2022-03-07 | Oncotracker Inc | Métodos mejorados para supervisar el estado inmunitario de un sujeto |
| US20170233484A1 (en) * | 2016-02-17 | 2017-08-17 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
| SG10202012157QA (en) | 2016-06-07 | 2021-01-28 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| EA201891851A1 (ru) * | 2016-09-16 | 2019-04-30 | Сиэтл Дженетикс, Инк. | Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений |
| US11446388B2 (en) | 2016-12-23 | 2022-09-20 | Heidelberg Pharma Research Gmbh | Amanitin antibody conjugates |
| CN108285489A (zh) * | 2017-01-09 | 2018-07-17 | 上海恒润达生生物科技有限公司 | 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途 |
| CN110582509A (zh) | 2017-01-31 | 2019-12-17 | 诺华股份有限公司 | 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症 |
| CN108395478A (zh) * | 2017-02-04 | 2018-08-14 | 上海恒润达生生物科技有限公司 | 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途 |
| IL268349B2 (en) | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| WO2018231944A1 (en) | 2017-06-13 | 2018-12-20 | Berenson James R | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| JP7585034B2 (ja) | 2017-10-18 | 2024-11-18 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
| SG11202004512XA (en) | 2017-11-15 | 2020-06-29 | Novartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
| BR112020010579A2 (pt) | 2017-11-30 | 2020-11-10 | Novartis Ag | receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo |
| TW201930591A (zh) | 2018-01-08 | 2019-08-01 | 瑞士商諾華公司 | 用於與嵌合抗原受體療法併用之免疫增強rna |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
| AU2019214183B2 (en) * | 2018-02-01 | 2022-04-07 | Innovent Biologics (Suzhou) Co., Ltd. | Fully human anti-B cell maturation antigen (BCMA) single chain variable fragment, and application thereof |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| KR20200123155A (ko) * | 2018-02-21 | 2020-10-28 | 셀진 코포레이션 | Bcma-결합 항체 및 이의 용도 |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| CA3100724A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof |
| CA3100187A1 (en) * | 2018-06-26 | 2020-01-02 | Abl Bio, Inc. | Anti-bcma antibody and use thereof |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| MD4324851T2 (ro) | 2018-07-19 | 2025-12-31 | Regeneron Pharma | Receptori antigenici chimerici cu specificitate BCMA și utilizările acestora |
| WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| CA3109959A1 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| SMT202400408T1 (it) | 2019-01-16 | 2024-11-15 | Caribou Biosciences Inc | Anticorpo umanizzato bcma e cellule bcma-car-t |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| US20220152150A1 (en) | 2019-02-25 | 2022-05-19 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| EP3942025A1 (en) | 2019-03-21 | 2022-01-26 | Novartis AG | Car-t cell therapies with enhanced efficacy |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US20220251152A1 (en) | 2019-04-24 | 2022-08-11 | Novartis Ag | Compositions and methods for selective protein degradation |
| AU2020270407A1 (en) * | 2019-05-03 | 2021-12-02 | Celgene Corporation | Anti-BCMA antibody conjugate, compositions comprising the same, and methods of making and using the same |
| PE20220568A1 (es) | 2019-05-21 | 2022-04-20 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas |
| MX2022001065A (es) | 2019-07-30 | 2022-02-14 | Shanghai Hansoh Biomedical Co Ltd | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. |
| EP4272837A3 (en) * | 2019-08-02 | 2024-02-28 | Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer | Car t-cells against bcma for the treatment of multiple myeloma |
| CA3149585A1 (en) * | 2019-09-25 | 2021-04-01 | Bahram VALMEHR | Multi-targeting effector cells and use thereof |
| US12479922B2 (en) | 2019-10-10 | 2025-11-25 | Cytolynx Therapeutics Hong Kong Limited | Humanized monoclonal antibody targeting BCMA and having human monkey cross-reactivity |
| PH12022551291A1 (en) | 2019-11-26 | 2023-11-20 | Novartis Ag | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
| WO2021121250A1 (zh) * | 2019-12-17 | 2021-06-24 | 深圳市菲鹏生物治疗股份有限公司 | Bcma结合抗体及其用途 |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| KR20220146530A (ko) | 2020-02-27 | 2022-11-01 | 노파르티스 아게 | 키메라 항원 수용체-발현 세포의 제조 방법 |
| KR20220147109A (ko) | 2020-02-27 | 2022-11-02 | 노파르티스 아게 | 키메라 항원 수용체 발현 세포의 제조 방법 |
| CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
| AR122546A1 (es) | 2020-06-05 | 2022-09-21 | Eisai R&D Man Co Ltd | Conjugados de anticuerpo anti bcma-fármaco y métodos de uso |
| CA3185455A1 (en) | 2020-06-11 | 2021-12-16 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| US20230302155A1 (en) | 2020-08-21 | 2023-09-28 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
| JP2023545099A (ja) | 2020-10-08 | 2023-10-26 | アフィメド ゲーエムベーハー | 三重特異性バインダー |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| CN112614596B (zh) * | 2020-12-22 | 2023-01-10 | 厦门承葛生物科技有限公司 | 一种肠道菌群移植治疗溃疡性结肠炎的供受体配型方法 |
| CA3214757A1 (en) | 2021-04-08 | 2022-10-13 | Andreas Loew | Multifuntional molecules binding to tcr and uses thereof |
| EP4330381A1 (en) | 2021-04-27 | 2024-03-06 | Novartis AG | Viral vector production system |
| US11931420B2 (en) | 2021-04-30 | 2024-03-19 | Celgene Corporation | Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI) |
| CA3216098A1 (en) | 2021-07-30 | 2023-02-02 | Uwe Reusch | Duplexbodies |
| WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| KR20240073006A (ko) | 2021-08-11 | 2024-05-24 | 사나 바이오테크놀로지, 인크. | 동종이계 세포 요법을 위한 유전자 변형된 1차 세포 |
| JP2024535677A (ja) | 2021-08-11 | 2024-10-02 | サナ バイオテクノロジー，インコーポレイテッド | 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞 |
| AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| JP2024531364A (ja) | 2021-08-20 | 2024-08-29 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| AU2022382368A1 (en) | 2021-11-03 | 2024-05-02 | Affimed Gmbh | Bispecific cd16a binders |
| KR20240155390A (ko) | 2022-02-17 | 2024-10-28 | 사나 바이오테크놀로지, 인크. | 조작된 cd47 단백질 및 이의 용도 |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| CN120112650A (zh) | 2022-10-26 | 2025-06-06 | 诺华股份有限公司 | 慢病毒配制品 |
| WO2024097315A2 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Cell therapy products and methods for producing same |
| JP2026510999A (ja) | 2023-03-21 | 2026-04-10 | バイオグラフ ５５，インク． | Ｃｄ１９／ｃｄ３８多重特異性抗体 |
| AU2024328949A1 (en) | 2023-08-23 | 2026-03-12 | Sana Biotechnology, Inc. | Modified cd47 proteins and their uses |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2025217258A1 (en) * | 2024-04-09 | 2025-10-16 | The Rockefeller University | Nptx1 antibodies |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030012783A1 (en) | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1532175B1 (en) | 2002-03-22 | 2012-10-17 | Aprogen, Inc. | Humanized antibody and process for preparing the same |
| CA2609269C (en) * | 2005-05-26 | 2014-08-05 | Seattle Genetics, Inc. | Humanized anti-cd40 antibodies and their methods of use |
| US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| WO2009070767A2 (en) * | 2007-11-28 | 2009-06-04 | Whitehead Institute For Biomedical Research | Systemic instigation systems to study tumor growth or metastasis |
| WO2010014629A1 (en) * | 2008-07-28 | 2010-02-04 | Trubion Pharmaceuticals, Inc. | Multi-specific binding proteins targeting b cell disorders |
| EP2406284B9 (en) * | 2009-03-10 | 2017-03-01 | Biogen MA Inc. | Anti-bcma antibodies |
| BRPI1014449A2 (pt) | 2009-04-07 | 2017-06-27 | Roche Glycart Ag | anticorpos biespecíficos anti-erbb-2/ anti-c-met. |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| US20130101599A1 (en) * | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| CA2833820C (en) * | 2011-05-27 | 2019-10-29 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| JP6694712B2 (ja) * | 2012-11-01 | 2020-05-20 | マックス−デルブルック−セントラム フアー モレキュラーレ メデジン | Ｃｄ２６９（ｂｃｍａ）に対する抗体 |
| KR102632731B1 (ko) * | 2014-04-30 | 2024-02-01 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Ｃｄ269에 대한 인간화 항체 |
-
2015
- 2015-04-30 KR KR1020237013978A patent/KR102632731B1/ko active Active
- 2015-04-30 US US15/306,438 patent/US10144782B2/en active Active
- 2015-04-30 RU RU2016146486A patent/RU2749041C2/ru active
- 2015-04-30 MX MX2016013767A patent/MX375800B/es active IP Right Grant
- 2015-04-30 EP EP15720954.5A patent/EP3137500A1/en active Pending
- 2015-04-30 SG SG11201608415QA patent/SG11201608415QA/en unknown
- 2015-04-30 KR KR1020227018383A patent/KR102526945B1/ko active Active
- 2015-04-30 KR KR1020167033409A patent/KR102405492B1/ko active Active
- 2015-04-30 RU RU2021115081A patent/RU2021115081A/ru unknown
- 2015-04-30 UA UAA201612087A patent/UA121031C2/uk unknown
- 2015-04-30 CN CN201580021693.5A patent/CN106661109B/zh active Active
- 2015-04-30 JP JP2016565168A patent/JP6755805B2/ja active Active
- 2015-04-30 BR BR112016024546-6A patent/BR112016024546A2/pt not_active Application Discontinuation
- 2015-04-30 WO PCT/EP2015/059562 patent/WO2015166073A1/en not_active Ceased
- 2015-04-30 CN CN202110761923.9A patent/CN113491776B/zh active Active
- 2015-04-30 IL IL303667A patent/IL303667A/en unknown
- 2015-04-30 IL IL248257A patent/IL248257B2/en unknown
- 2015-04-30 AU AU2015254526A patent/AU2015254526B2/en active Active
- 2015-04-30 NZ NZ725701A patent/NZ725701A/en unknown
-
2016
- 2016-10-12 ZA ZA2016/07018A patent/ZA201607018B/en unknown
- 2016-10-20 MX MX2020010530A patent/MX2020010530A/es unknown
-
2018
- 2018-10-25 US US16/170,575 patent/US10851172B2/en active Active
-
2020
- 2020-08-26 JP JP2020142486A patent/JP7189913B2/ja active Active
- 2020-10-23 US US17/079,075 patent/US11820829B2/en active Active
-
2022
- 2022-12-05 JP JP2022194533A patent/JP2023025202A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023025202A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| TWI640537B (zh) | ＰＤＧＦ受體β結合多肽 | |
| JP6643350B2 (ja) | Ｃｄ４７に結合する抗体医薬 | |
| JP2017530722A5 (https=) | ||
| JP2021524267A5 (https=) | ||
| JP2025134874A (ja) | ブラジキニンｂ１受容体リガンドに対する抗体 | |
| JP7745113B2 (ja) | 多重特異性抗体およびその使用 | |
| JP2017515470A5 (https=) | ||
| EP3897719A1 (en) | Protease cleavable bispecific antibodies and uses thereof | |
| JP2012034692A5 (https=) | ||
| WO2013039954A1 (en) | Anti-gitr antibodies | |
| JP2014076062A5 (https=) | ||
| JP2009502171A5 (https=) | ||
| JP2022513420A5 (https=) | ||
| JP2010503386A5 (https=) | ||
| JP2005526501A5 (https=) | ||
| JP2013537418A5 (https=) | ||
| EP3265486A2 (en) | Antibody therapeutics that bind tim3 | |
| JP2012518404A5 (https=) | ||
| JP2019507183A5 (https=) | ||
| JP2010511388A5 (https=) | ||
| JP2008508864A5 (https=) | ||
| JP2016513467A5 (https=) | ||
| JP2015509097A5 (https=) |